Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen
ORi to Be Launched in the U.S. at ANESTHESIOLOGY 2023 This WeekendSAN FRANCISCO--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that ORi™,...